Genmab

We want to hear from you! Please participate in the below poll:  

Cervical cancer is the fourth leading cause of cancer-related death among women globally. That’s why we partnered with Pfizer to create #CeMe, a valuable resource for the cervical cancer community that aims to raise awareness about the disease, share diverse patient perspectives, and foster meaningful connections to help those navigating a diagnosis feel seen and heard. http://xmrrwallet.com/cmx.pgmab.ly/FTOe50WvOoV

Cervical cancer is the 14th most frequent cancer among women in the U.S. It is estimated that more than 13,000 women in the U.S. will be diagnosed with invasive cervical cancer this year, which is why increased awareness is crucial for early detection and prevention. Through #CeMe, a disease-awareness initiative created in partnership with Pfizer that aims to amplify the voices of the cervical cancer patient community, we can help shed light on the lived experiences of those navigating a diagnosis and drive greater awareness. http://xmrrwallet.com/cmx.pgmab.ly/SeSj50WvtWq

In honor of #NationalInternDay, we thank our passionate and motivated summer interns for their dedication to advancing science and bringing antibody medicines to patients in need.     This summer, our interns in the Netherlands and the U.S. are contributing to our impactful work, engaging in meaningful projects and connecting with our colleagues.    Today we reflect on our own internship experiences and thank those who came before us for their mentorship and support in guiding the next generation of innovators.    #Internship 

Why embedding the patient perspective isn’t just good practice, it’s essential.     In this edition of Antibody Hour 🕙—unveiling the stories driving antibody innovation, our colleague Shawn Keogan, PhD, Director of Patient Advocacy, shares how we’re genuinely listening to patients, absorbing their insights, with the intent of turning these insights into actions - because patients aren’t just stakeholders, they're experts in their experience.    #AntibodyHour #PatientFirst #Innovation 

#ICYMI: At Genmab, we believe that transforming the lives of patients starts with empowering our people. From research to discovery to commercialization, everyone brings their own unique expertise to Genmab and is encouraged to share ideas, and spark innovation—united by our shared vision to transform the lives of people with cancer and other serious diseases.      This week on #AntibodyHour 🕙, hear from Ewan Robson PhD, Senior Director, EU Medical Affairs, and Francis Blokzijl, PhD, Senior Scientist, Data Science, as they discuss how this open culture fuels collaboration and continues to inspire our team to advance innovations in antibody medicines for patients.   #Innovation #culture 

Scientific innovation powers our progress—from our deep expertise in antibody therapies to how we advance our late-stage pipeline. At Genmab, our approach to disease biology is grounded in purpose, and our R&D teams are fueled by deep curiosity and bold thinking.    Dive deeper and explore how we're working to shape the future of antibody science to potentially deliver targeted treatment for patients: https://xmrrwallet.com/cmx.plnkd.in/evvAnxBf.    #AntibodyInnovation #AntibodyScience 

Welcome to Genmab’s July Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare

Leadership Update at Genmab After 23 remarkable years, Birgitte Stephensen, EVP & Chief Legal Officer, will retire from Genmab. We extend our heartfelt thanks to Birgitte for her outstanding leadership and for helping shape Genmab’s journey into a biotech innovation powerhouse. We are also pleased to welcome Greg Mueller as our new EVP, General Counsel & Chief Legal Officer, effective July 1. Greg will lead Genmab’s global legal affairs, intellectual property, corporate governance, and compliance functions. He joins us from AstraZeneca with a strong track record leading teams across North America, Europe, and Asia. Please join us in honoring Birgitte on her retirement and welcoming Greg as we continue our transformation into a fully integrated biotech company bringing innovative antibody-based medicines to patients. Learn more: https://xmrrwallet.com/cmx.plnkd.in/evQxbWBz. #Leadership #Biotech

🎉 We’re thrilled to announce the grand opening of our expanded site in New Jersey, a vibrant space built for innovation, collaboration & our #OneGenmab spirit.    We’re grateful to mark this moment with patient advisors, community leaders, government officials, academic partners, and our incredible Genmab colleagues.     This expansion deepens our roots in New Jersey’s thriving life sciences ecosystem and moves us closer to our vision: bringing knock-your-socks-off (KYSO) antibody therapies® to patients.    Princeton University, BioNJ, New Jersey Economic Development Authority (NJEDA), Tennille R. McCoy, MBA, MLER, Crossroads4Hope, Township of Plainsboro, Portia Badham #Genmab #Biotech #Growth